Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1(Amended to 24-Weeks)

NCT00784147 is registered in ClinicalTrials.gov with TaiMed Biologics Inc. as lead sponsor.

NCT NCT00784147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00784147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1(Amended to 24-Weeks)
Lead sponsor
TaiMed Biologics Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
April 30, 2011
Enrollment
113 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hiv